Parallel variations of insulin-like peptide 3 (INSL3) and Antimüllerian Hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 10, 2013, Pages

  Pelusi, Carla ^a   Fanelli, Flaminia ^a   Pariali, Milena ^a   Zanotti, Laura ^a   Gambineri, Alessandra ^a   Pasquali, Renato ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN LIKE FACTOR 3; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; PEPTIDE HORMONE; PROGESTERONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AMENORRHEA; ANOVULATION; ARTICLE; CONTROLLED STUDY; FEMALE; HIRSUTISM; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; LUTEAL PHASE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OLIGOMENORRHEA; ORGAN SIZE; OVARIAN VOLUME; OVARY CYCLE; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROSPECTIVE STUDY; SCORING SYSTEM; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; AMENORRHEA; ANTI-MULLERIAN HORMONE; BODY WEIGHT; FEMALE; FOLLICLE STIMULATING HORMONE; HIRSUTISM; HUMANS; HYPERANDROGENISM; INSULIN; MENSTRUAL CYCLE; OVARIAN FOLLICLE; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; PROTEINS;

EID: 84885201775     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1107     Document Type: Article

References (44)

1. Ivell R, Anand-Ivell R. Biological role and clinical significance of insulin-like peptide 3. Curr Opin Endocrinol Diabetes Obes. 2011; 18: 210-216.
2. Broekmans FJ, Visser JA, Laven J.S., Broer SL, Themmen AP, Fauser BC Anti-Müllerian hormone and ovarian dysfunction. Trends Endocrinol Metab. 2008; 19: 340-347.
3. Lee MM, Donahoe PK Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev. 1993; 14: 152-164.
4. van Houten E.L., Themmen AP, Visser JA Anti-Mullerian hormone (AMH): regulator and marker of ovarian function. Ann Endocrinol (Paris). 2010; 71: 191-197.
5. Homburg R, Ray A, Bhide P., et al The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod. 2013; 28: 1077-1083.
6. Foresta C, Bettella A, Vinanzi C., et al A novel circulating hormone of testis origin in humans. J Clin Endocrinol Metab. 2004; 89: 5952-5958.
7. Nichols N, Binta H, Fields P.A., et al Immunohistochemical localization of relaxin-like factor/insulin-like peptide-3 in the bovine corpus luteum. Ann NY Acad Sci. 2005; 1041: 506-509.
8. Bamberger AM, Ivell R, Balvers M., et al Relaxin-like factor (RLF): a new specific marker for Leydig cells in the ovary. Int J Gynecol Pathol. 1999; 18: 163-168.
9. Irving-Rodgers H.F., Bathgate RA, Ivell R, Domagalski R., Rodgers RJ Dynamic changes in the expression of relaxin-like factor (INSL3), cholesterol side-chain cleavage cytochrome p450, and 3β-hydroxysteroid dehydrogenase in bovine ovarian follicles during growth and atresia. Biol Reprod. 2002; 66: 934-943.
10. Satchell L, Glister C, Bleach E.C., et al Ovarian expression of Insulin-Like Peptide 3 (INSL3) and its receptor (RXFP2) during development of bovine antral follicles and corpora lutea and measurement of circulating INSL3 levels during synchronized estrous cycles. Endocrinology. 2013; 154: 1897-1906.
11. Durlinger AL, Visser JA, Themmen AP Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction. 2002; 124: 601-609.
12. Themmen AP. Anti-Mullerian hormone: its role in follicular growth initiation and survival and as an ovarian reserve marker. J Natl Cancer Inst Monogr. 2005; 18-21.
13. Pigny P, Jonard S, Robert Y., Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91: 941-945.
14. Laven JS, Mulders AG, Visser J.A., Themmen AP, De Jong FH, Fauser BC Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004; 89: 318-323.
15. Catteau-Jonard S., Bancquart J, Poncelet E., Lefebvre-Maunoury C, Robin G, Dewailly D. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome? Ultrasound Obstet Gynecol. 2012; 40: 223-229.
16. Gambineri A, Patton L, De Iasio R, Palladoro F, Pagotto U., Pasquali R. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92: 2066-2073.
17. Anand-Ivell R., Dai Y, Ivell R. Neohormones as biomarkers of reproductive health. Fertil Steril. 2013; 99: 1153-1160.
18. Begawy AF, El-Mazny AN, Abou-Salem NA, El-Taweel NE. Anti-Mullerian hormone in polycystic ovary syndrome and normo-ovulatory women: Correlation with clinical, hormonal and ultrasonographic parameters. Middle East Fertil. Soc. J. 2010; 15: 253-258.
19. Gambineri A, Patton L, Prontera O., et al Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome. J Endocrinol Invest. 2011; 34: 685-691.
20. Pellatt L, Rice S, Mason HD Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010; 139: 825-833.
21. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update. 2004; 10: 107-117.
22. Piouka A, Farmakiotis D, Katsikis I., Macut D, Gerou S, Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009; 296: E238-E243.
23. La Marca A., Orvieto R, Giulini S., Jasonni VM, Volpe A, De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril. 2004; 82: 970-972.
24. Yding Andersen C., Rosendahl M, Byskov AG Concentration of anti-Müllerian hormone and inhibin-B in relation to steroids and age in follicular fluid from small antral human follicles. J Clin Endocrinol Metab. 2008; 93: 2344-2349.
25. Grynberg M, Pierre A, Rey R., et al Differential regulation of ovarian anti-Müllerian hormone (AMH) by estradiol through α- and β-estrogen receptors. J Clin Endocrinol Metab. 2012; 97: E1649-E1657.
26. Burgers JA, Fong SL, Louwers Y.V., et al Oligoovulatory and anovulatory cycles in women with polycystic ovary syndrome (PCOS): what's the difference? J Clin Endocrinol Metab. 2010; 95: E485-E489.
27. Barber TM, Wass JA, McCarthy M.I., Franks S. Metabolic characteristics of women with polycystic ovaries and oligoamenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007; 66: 513-517.
28. Carmina E, Chu MC, Longo R.A., Rini GB, Lobo RA Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005; 90: 2545-2549.
29. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
30. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961; 21: 1440-1447.
31. Ross GT, Cargille CM, Lipsett M.B., et al Pituitary and gonadal hormones in women during spontaneous and induced ovulatory cycles. Recent Prog Horm Res. 1970; 26: 1-62.
32. Israel R, Mishell DR Jr, Stone SC, Thorneycroft IH, Moyer DL Single luteal phase serum progesterone assay as an indicator of ovulation. Am J Obstet Gynecol. 1972; 112: 1043-1046.
33. Orsini LF, Venturoli S, Lorusso R., Pluchinotta V, Paradisi R, Bovicelli L. Ultrasonic findings in polycystic ovarian disease. Fertil Steril. 1985; 43: 709-714.
34. Vermeulen A, Verdonck L, Kaufman JM A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84: 3666-3672.
35. Matthews DR, Hosker JP, Rudenski A.S., Naylor BA, Treacher DF, Turner RC Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-419.
36. Webber LJ, Stubbs S, Stark J., et al Formation and early development of follicles in the polycystic ovary. Lancet. 2003; 362: 1017-1021.
37. Vendola K, Zhou J, Wang J., Famuyiwa OA, Bievre M, Bondy CA Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod. 1999; 61: 353-357.
38. Weil SJ, Vendola K, Zhou J., et al Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab. 1998; 83: 2479-2485.
39. Das M, Djahanbakhch O, Hacihanefioglu B., et al Granulosa cell survival and proliferation are altered in polycystic ovary syndrome. J Clin Endocrinol Metab. 2008; 93: 881-887.
40. Bathgate R, Balvers M, Hunt N., Ivell R. Relaxin-like factor gene is highly expressed in the bovine ovary of the cycle and pregnancy: sequence and messenger ribonucleic acid analysis. Biol Reprod. 1996; 55: 1452-1457.
41. Roche PJ, Butkus A, Wintour E.M., Tregear G. Structure and expression of Leydig insulin-like peptide mRNA in the sheep. Mol Cell Endocrinol. 1996; 121: 171-177.
42. Zarreh-Hoshyari-Khah MR, Einspanier A, Ivell R. Differential splicing and expression of the relaxin-like factor gene in reproductive tissues of the marmoset monkey (Callithrix jacchus). Biol Reprod. 1999; 60: 445-453.
43. Kawamura K, Kumagai J, Sudo S., et al Paracrine regulation of mammalian oocyte maturation and male germ cell survival. Proc Natl Acad Sci USA. 2004; 101: 7323-7328.
44. Pathirana IN, Kawate N, Büllesbach EE, et al Insulin-like peptide 3 stimulates testosterone secretion in mouse Leydig cells via cAMP pathway. Regul Pept. 2012; 178: 102-106.